NasdaqCM:ENTX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Entera Bio's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ENTX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.3%

ENTX

0.5%

US Biotechs

1.7%

US Market


1 Year Return

-45.5%

ENTX

23.3%

US Biotechs

8.5%

US Market

Return vs Industry: ENTX underperformed the US Biotechs industry which returned 23.3% over the past year.

Return vs Market: ENTX underperformed the US Market which returned 8.5% over the past year.


Shareholder returns

ENTXIndustryMarket
7 Day-3.3%0.5%1.7%
30 Day1.8%7.7%9.5%
90 Day-31.9%9.0%0.1%
1 Year-45.5%-45.5%24.5%23.3%11.0%8.5%
3 Yearn/a34.3%29.8%32.2%23.5%
5 Yearn/a-3.7%-9.5%58.6%40.8%

Price Volatility Vs. Market

How volatile is Entera Bio's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Entera Bio undervalued compared to its fair value and its price relative to the market?

3.52x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ENTX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ENTX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ENTX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ENTX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ENTX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ENTX is good value based on its PB Ratio (3.5x) compared to the US Biotechs industry average (3.7x).


Next Steps

Future Growth

How is Entera Bio forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

48.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ENTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ENTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ENTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ENTX's revenue (85.8% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: ENTX's revenue (85.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ENTX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Entera Bio performed over the past 5 years?

-23.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ENTX is currently unprofitable.

Growing Profit Margin: ENTX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ENTX is unprofitable, and losses have increased over the past 5 years at a rate of -23.1% per year.

Accelerating Growth: Unable to compare ENTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ENTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: ENTX has a negative Return on Equity (-107.02%), as it is currently unprofitable.


Next Steps

Financial Health

How is Entera Bio's financial position?


Financial Position Analysis

Short Term Liabilities: ENTX's short term assets ($14.1M) exceed its short term liabilities ($5.0M).

Long Term Liabilities: ENTX's short term assets ($14.1M) exceed its long term liabilities ($203.0K).


Debt to Equity History and Analysis

Debt Level: ENTX is debt free.

Reducing Debt: ENTX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ENTX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ENTX has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 28.5% each year.


Next Steps

Dividend

What is Entera Bio's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ENTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ENTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ENTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ENTX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ENTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Adam Gridley (47yo)

0.83

Tenure

US$787,719

Compensation

Mr. Adam D. Gridley serves as Chief Executive Officer of Entera Bio Ltd. since August 5, 2019 and has been its Director since November 2019. Mr. Gridley serves as a Member of the board of advisors for Life ...


CEO Compensation Analysis

Compensation vs Market: Adam's total compensation ($USD787.72K) is above average for companies of similar size in the US market ($USD591.64K).

Compensation vs Earnings: Insufficient data to compare Adam's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Adam Gridley
CEO & Director0.83yrUS$787.72kno data
Hillel Galitzer
Chief Operating Officer6.33yrsUS$367.39k0.39% $138.8k
Phillip Schwartz
Executive VP10.42yrsUS$722.01k3.18% $1.1m
Arthur Santora
Chief Medical Officer1.75yrsUS$445.48kno data
Dana Yaacov-Garbeli
Chief Financial Officer0.42yrno datano data
Roger Garceau
Chief Development Advisor & Director4.25yrsUS$378.34k0.027% $9.6k
Jonathan Lieber
US Chief Financial Officer0.42yrno datano data

0.8yrs

Average Tenure

53yo

Average Age

Experienced Management: ENTX's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Adam Gridley
CEO & Director0.83yrUS$787.72kno data
Phillip Schwartz
Executive VP10.42yrsUS$722.01k3.18% $1.1m
Roger Garceau
Chief Development Advisor & Director4.25yrsUS$378.34k0.027% $9.6k
Gerald Lieberman
Independent Chairman of the Board1.83yrsUS$500.12k0.54% $189.3k
Gerald Ostrov
Independent Director1.42yrsno datano data
Zeev Bronfeld
Director10.42yrsno datano data
Yonatan Malca
Director9.42yrsno datano data
Miranda Toledano
Independent External Director1.75yrsno datano data
Faith Charles
External Director1.75yrsUS$126.99kno data
Sean Ellis
Director1yrno datano data

1.8yrs

Average Tenure

57yo

Average Age

Experienced Board: ENTX's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 59.1%.


Top Shareholders

Company Information

Entera Bio Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Entera Bio Ltd.
  • Ticker: ENTX
  • Exchange: NasdaqCM
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$35.272m
  • Shares outstanding: 18.23m
  • Website: https://www.enterabio.com

Number of Employees


Location

  • Entera Bio Ltd.
  • Minrav Building
  • Fifth Floor
  • Jerusalem
  • 9112002
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ENTXNasdaqCM (Nasdaq Capital Market)YesOrdinary SharesUSUSDJun 2018

Biography

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company’s lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/03 05:06
End of Day Share Price2020/06/02 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.